Ozon Pharmaceuticals
MMOEX:OZPH46.68
RUB
-0.79
(-1.66%)
ISIN
RU000A109B25
Return %
Stock
S&P 500
1Y
-6.73
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Eric Falkeis
- Full Time Employees
- 135
- Address
- building No. 1 Samara
- IPO Date
- Oct 17, 2024
- Website
- ozonpharm.ru
- Similar Companies
- Business
- Ozon Pharmaceuticals, a pharmaceutical manufacturer and marketer, operates across multiple regions with a focus on prescription medicines and a diversified portfolio spanning pain management, anti-infectives, cardiovascular and metabolic therapies, hematology/hemostats, and nutritional supplements. Main products and services - Prescription medicines: analgesics and pain management formulations; anti-infective agents; cardiovascular and metabolic disease therapies; diabetes management drugs; hematology/hemostasis products; vascular and chronic disease treatment portfolios. - Dosing forms and delivery: tablets, capsules, injectables; specialized and pediatric formulations; sterile products and complex generics. - Brand and portfolio management: proprietary brands and branded generic lines; private-label and contract manufacturing services for third parties; regulatory and quality assurance oversight for product development and lifecycle management. - Research and development: in-house R&D facilities supporting formulation development, clinical-grade trials, process optimization, and regulatory submissions; NABL-accredited capabilities underpinning quality and compliance. - Manufacturing and packaging: bulk manufacturing, fill-finish operations, packaging customization, and scale-up for regional and international distribution. - Distribution and marketing: field-based sales forces targeting physicians and specialists; multi-channel marketing and distributor networks across domestic and international markets. Geographic operations and structure - Headquarters and primary operations located in India with manufacturing facilities in key states; regional marketing and distribution networks in India and neighboring markets; expansion into international markets, including GCC and select global regions through strategic collaborations and localized manufacturing programs. - Regional manufacturing footprint includes multiple plants to support a diversified product mix, with plans for further capacity expansion and geographic diversification. Founding year and leadership - Founded in the early 1990s; headquartered in India. The group operates under a multi-unit corporate structure with integrated manufacturing and marketing subsidiaries, and strategic alliances to extend global reach. Subsidiaries and relationships - Ozon Group of Companies encompasses pharmaceutical manufacturing, beauty and cosmetics, wellness, and skill development divisions; operates through branded portfolios and partnerships with international cosmetic names for distribution and co-development; maintains strategic alliances to scale manufacturing and market access. Latest major changes - Strategic expansion into international manufacturing and regional markets via new facility developments and partnerships; ongoing capacity expansion investments targeting higher production of tablets and final dosage forms for GCC and regional markets; alliances with global cosmetic brands to distribute premium skincare and haircare products in India and abroad; active pursuit of new product launches and line extensions in pain management, anti-infectives, and chronic disease therapies. - Notable recent activity includes establishing a manufacturing footprint in Dubai Industrial City to serve GCC and neighboring regions, with phased investments and significant capacity planned, signaling a shift toward broader regional production and export-oriented growth. Industry context and customers - Industry: generic and branded pharmaceutical manufacturing and marketing; segments include prescription medicines, nutraceuticals, and dermo-cosmetics through related business lines. - Customer base includes hospitals, clinics, specialty physicians, distributors, pharmacies, and end consumers, with a focus on access to affordable medicines in diabetes and cardiac care. - Markets pursued include India, Nepal, GCC countries, and select international markets via partnerships and local manufacturing arrangements. Note: This description reflects current publicly available information and highlights the company's core products and services, recent strategic activities, and geographic footprint as of the latest updates.